ARMP (Armata Pharmaceuticals) Moat Score: 3/10 (As of Jun. 27, 2026)


ARMP Armata Pharmaceuticals Inc ARMP
27 GF Score
Price $7.40
! 3 Warning Signs
View Full Analysis

What is Armata Pharmaceuticals Moat Score?

Armata Pharmaceuticals ARMP +13.85% 27 Moat Score is 3 as of Jun. 27, 2026. GuruFocus rates ARMP with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,404 Biotechnology companies, Armata Pharmaceuticals ranks better than 75.5% on this metric.

Armata Pharmaceuticals has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Armata Pharmaceuticals has No Moat: Armata Pharmaceuticals has very weak competitive advantages. While it may possess some valuable intellectual property, it lacks market leadership, significant customer switching costs, and strong brand strength. The biotech industry is highly competitive, and Armata does not have a durable cost advantage or regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Armata Pharmaceuticals might have No Moat - Very weak/transient advantages.

Armata Pharmaceuticals  (AMEX:ARMP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Armata Pharmaceuticals Moat Score Related Terms

ARMP vs SRZN, ELDN, NAGE: Moat Score Comparison

For the Biotechnology subindustry, Armata Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Armata Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's Moat Score falls into.


ARMP
27GF Score
Armata Pharmaceuticals Inc ARMP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Armata Pharmaceuticals (ARMP) has a Moat Score of 3 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Armata Pharmaceuticals ranks #344 out of 1404 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Armata Pharmaceuticals' Moat Score too high?
Armata Pharmaceuticals' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Armata Pharmaceuticals' value of 3 is 50% above this industry median. Based on the distribution chart, Armata Pharmaceuticals ranks #344 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Armata Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Armata Pharmaceuticals' Moat Score compare to SRZN and ELDN?
According to the Biotechnology industry distribution chart, Armata Pharmaceuticals ranks #344 out of 1404 companies for Moat Score. This places Armata Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Armata Pharmaceuticals' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Armata Pharmaceuticals's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Armata Pharmaceuticals's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Armata Pharmaceuticals stock overvalued right now?
Armata Pharmaceuticals (ARMP) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Armata Pharmaceuticals' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Armata Pharmaceuticals (ARMP), the current Moat Score is 3 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Armata Pharmaceuticals Business Description

Other Exchanges TG1N:Germany
Address 5005 McConnell Avenue, Los Angeles, CA, USA, 90066
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
27GF Score

Get the complete analysis for ARMP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.40
Price